ARTICLES BY THIS AUTHOR
- 3/17/2022
Excluding virtual healthcare will do more harm
Ontario's Proposed Physician Services Agreement will drastically cut physician fees for virtual care provided to patients seeing a new doctor thus disadvantaging patients who don’t have an FP, argues Dr. Brett Belchetz, CEO of Maple. - 3/17/2022
We have 15 minutes today
Patients tell me frequently that they don’t know that their appointment has a time limit. We need to tell them. - 3/17/2022
NACI recommends kids get Pfizer COVID-19 vaccine, calls Moderna suitable alternative
Moderna's vaccine does appear to be slightly more effective, according to indirect data in the adult population. - 3/17/2022
B.C. doctors and medical learners have chosen a new CMA president-elect
A former Doctors of BC president, Dr. Kathleen Ross is a family doctor based in Coquitlam and New Westminster. - 3/17/2022
Research director to resign from Ontario COVID-19 science table
A spokeswoman says Dr. Peter Juni hasn't set a date when he will officially step down. - 3/16/2022
Scientists explore potential connection between diabetes and COVID-19
Emerging evidence shows that the coronavirus—like some other viruses—can attack insulin-producing cells in the pancreas—a process that might trigger at least temporary diabetes in susceptible people. - 3/16/2022
Navigating purgatory with Ontario's proposed fee deal
Dr. Sharadindu Rai argues the lack of a clear 'yes' or 'no' means the perceived concerns and benefits of the PPSA vary greatly from one physician to another. - 3/16/2022
How the PPSA makes family medicine worse?
Fights to get into FHOs, more work for less pay, more ministry oversight of practices, worsening relativity and gender pay gap – all 'hidden' aspects of Ontario's proposed fee deal says Dr. Alykhan Abdulla. - 3/16/2022
WHO may reject Canadian made Medicago COVID-19 vaccine because of ties to big tobacco
The two-dose Medicago Covifenz vaccine was authorized in Canada last month for adults between 18 and 64 years old. - 3/16/2022
More than 30 companies to start making Pfizer's COVID pill
The Medicines Patent Pool said in a statement that agreements signed with 35 companies should help make Pfizer's antiviral nirmatrelvir, or Paxlovoid, available to more than half of the world's population.